LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Enfermedad de Hansen. Comunicación de un caso de lepra tuberculoide en Chile.

    Armijo, Daniela / Aguirre, Franco / Raimann, María Victoria / Costa, Felipe da / Barría, Carlos

    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia

    2022  Volume 39, Issue 1, Page(s) 80–85

    Abstract: Hansen's disease or leprosy is a chronic infectious disease caused by Mycobacterium leprae, mainly affecting the skin and peripheral nerves. In recent years, a better control of the disease has been achieved globally. However, in Chile the incidence of ... ...

    Title translation Hansen's disease. Case report of tuberculoid leprosy in Chile.
    Abstract Hansen's disease or leprosy is a chronic infectious disease caused by Mycobacterium leprae, mainly affecting the skin and peripheral nerves. In recent years, a better control of the disease has been achieved globally. However, in Chile the incidence of leprosy has continued to increase. We present a case of a 40-year-old patient Haitian nationality with lesions and histopathology compatible with tuberculoid leprosy. We discuss the importance of education on less prevalent diseases in Chile, in conjunction with a review of the pathophysiology, clinic, and classification of Hansen's disease.
    MeSH term(s) Adult ; Chile ; Haiti ; Humans ; Leprosy ; Leprosy, Tuberculoid/diagnosis ; Leprosy, Tuberculoid/drug therapy ; Mycobacterium leprae
    Language Spanish
    Publishing date 2022-06-23
    Publishing country Chile
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2048815-4
    ISSN 0717-6341 ; 0716-1018
    ISSN (online) 0717-6341
    ISSN 0716-1018
    DOI 10.4067/S0716-10182022000100080
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Lichenoid skin lesions: A rare manifestation in secondary syphilis.

    Armijo, Daniela / Valenzuela, Fernando / Stevens, Jonathan / Morales, Claudia

    Indian journal of dermatology, venereology and leprology

    2019  Volume 86, Issue 1, Page(s) 105

    MeSH term(s) Adult ; Humans ; Lichenoid Eruptions/etiology ; Lichenoid Eruptions/pathology ; Male ; Syphilis/complications ; Syphilis/pathology
    Language English
    Publishing date 2019-02-21
    Publishing country India
    Document type Case Reports ; Letter
    ZDB-ID 416068-x
    ISSN 0973-3922 ; 0019-5162 ; 0378-6323
    ISSN (online) 0973-3922
    ISSN 0019-5162 ; 0378-6323
    DOI 10.4103/ijdvl.IJDVL_200_18
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis.

    Maul, Julia-Tatjana / Fröhlich, Fabienne / Maul, Lara Valeska / Stunnenberg, Rieka / Valenzuela, Fernando / De La Cruz, Claudia / Vera-Kellet, Cristián / Armijo, Daniela / Cesar, Wagner G / Carvalho, Andre / Didaskalu, Johannes Alexander / Graf, Nicole / Egeberg, Alexander / Wu, Jashin J / Thyssen, Jacob P / Romiti, Ricardo / Griffiths, Christopher E M

    The British journal of dermatology

    2023  Volume 188, Issue 4, Page(s) 533–541

    Abstract: Background: Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Brazil and Chile are lacking. Understanding the availability and limiting factors of access to treatments can help to improve ... ...

    Abstract Background: Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Brazil and Chile are lacking. Understanding the availability and limiting factors of access to treatments can help to improve patient care and decrease long-term healthcare costs.
    Objectives: In association with the Global Psoriasis Atlas, this cross-sectional survey study analysed the availability and insurance reimbursement of systemic treatments for adult patients with psoriasis in Brazil and Chile.
    Methods: A multicentre, cross-sectional Global Healthcare Study on Psoriasis was performed in Brazil and Chile in 2020. For each eligible adult patient with psoriasis, doctors and nurses completed a 48-item questionnaire about clinical aspects of psoriasis including the Psoriasis Area Severity Index (PASI), body surface area (BSA) score and the Dermatology Life Quality Index (DLQI), as well as the availability of systemic treatments and insurance reimbursement status. Between-country differences were compared with Wilcoxon rank sum tests for continuous variables, and a χ2-test or Fisher's exact test, where appropriate, for categorical variables. The median and interquartile range (IQR) was calculated for non-normal distributed data.
    Results: A total of 1424 patients with psoriasis from 43 centres [27 centres in Brazil (n = 826) and 16 in Chile (n = 598)], were included with a mean (SD) age of 49.1 (16.3) and 49.2 (15.1) years, respectively. Unstratified analyses revealed that patients with psoriasis in Chile had more severe disease than those in Brazil [PASI 11.6 vs. 8.4 (P < 0.001) and BSA 14.7 vs. 12.0 (P = 0.003), respectively]. For patients with moderate-to-severe psoriasis, defined as PASI and/or BSA ≥ 10, systemic nonbiologic drugs were available (81.2% in Brazil and 65.3% in Chile, P ≤ 0.001), but only 37.0% of patients in Brazil and 27.3% in Chile received biologics (P = 0.01). Lack of availability and/or lack of insurance reimbursement for biologic drugs for patients with moderate-to-severe psoriasis was reported for 22.2% (50 of 225) in Brazil and 67.9% (148 of 218) in Chile (P < 0.001). Patients with no access to biologic therapies due to lack of availability/insurance reimbursement had a median PASI of 9.15 (IQR 3.00-14.25) in Brazil and 12.0 (IQR 5.00-19.00) in Chile (P = 0.007), as well as a median BSA of 7.0 (IQR 3.00-15.00) and 12.0 (IQR 5.00-22.50) (P = 0.002), and median DLQI of 11.0 (6.00-15.00) and 21.0 (6.50-25.00) (P = 0.007), respectively.
    Conclusions: Chilean patients had significantly more severe psoriasis compared with Brazilian patients in our study. While nonbiologic treatments for moderate-to-severe psoriasis were available in both LA countries, there is a high need for improvement in access to more effective psoriasis treatments including biologics. Our results highlight a significant gap between treatment recommendations in international psoriasis guidelines and real-world situations in Brazil and Chile.
    MeSH term(s) Adult ; Humans ; Cross-Sectional Studies ; Brazil/epidemiology ; Chile/epidemiology ; Quality of Life ; Psoriasis/drug therapy ; Treatment Outcome ; Health Care Costs ; Biological Products/therapeutic use ; Severity of Illness Index
    Chemical Substances Biological Products
    Language English
    Publishing date 2023-01-19
    Publishing country England
    Document type Multicenter Study ; Journal Article
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1093/bjd/ljac128
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis.

    Valenzuela, Fernando / De La Cruz, Claudia / Lecaros, Cristóbal / Fernández, Javier / Hevia, Gonzalo / Maul, Lara Valeska / Thyssen, Jacob P / Vera-Kellet, Cristián / Egeberg, Alexander / Armijo, Daniela / Pizarro, Cristian / Riveros, Tatiana / Correa, Hernán / Guglielmetti, Antonio / Didaskalu, Johannes A / Wu, Jashin J / Griffiths, Christopher E M / Romiti, Ricardo / Maul, Julia-Tatjana

    Clinical and experimental dermatology

    2022  Volume 47, Issue 12, Page(s) 2234–2241

    Abstract: Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America.: Aim: To examine the comorbidity ... ...

    Abstract Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America.
    Aim: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis.
    Methods: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression.
    Results: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 ± 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 ± 11.5; body surface area 14.7 ± 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis.
    Conclusions: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
    MeSH term(s) Male ; Female ; Humans ; Non-alcoholic Fatty Liver Disease/epidemiology ; Chile/epidemiology ; Diabetes Mellitus, Type 2/epidemiology ; Cross-Sectional Studies ; Psoriasis/epidemiology ; Comorbidity ; Obesity/epidemiology ; Dyslipidemias ; Delivery of Health Care
    Language English
    Publishing date 2022-10-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1111/ced.15384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.

    Navarrete-Dechent, Cristián / Majerson, Daniela / Torres, Marisa / Armijo, Daniela / Patel, Mahir / Menter, Alan / de la Cruz, Claudia

    Anais brasileiros de dermatologia

    2015  Volume 90, Issue 3 Suppl 1, Page(s) 171–174

    Abstract: There are several studies on the benefits of using TNFα antagonists in the treatment of psoriasis, but few studies addressing the interaction of these drugs with chronic infections. We report the case of a 52-year-old patient diagnosed with psoriasis ... ...

    Abstract There are several studies on the benefits of using TNFα antagonists in the treatment of psoriasis, but few studies addressing the interaction of these drugs with chronic infections. We report the case of a 52-year-old patient diagnosed with psoriasis refractory to traditional systemic agents, who was treated with biologic therapies. After one year of treatment with biologic agents, the patient was diagnosed with Chagas Disease.
    MeSH term(s) Adalimumab/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Biological Factors/therapeutic use ; Biological Therapy/methods ; Chagas Disease/drug therapy ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction ; Psoriasis/drug therapy ; Reproducibility of Results ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Anti-Inflammatory Agents ; Biological Factors ; Tumor Necrosis Factor-alpha ; Adalimumab (FYS6T7F842)
    Language English
    Publishing date 2015-07-29
    Publishing country Spain
    Document type Case Reports ; Journal Article
    ZDB-ID 433655-0
    ISSN 1806-4841 ; 0365-0596
    ISSN (online) 1806-4841
    ISSN 0365-0596
    DOI 10.1590/abd1806-4841.20153538
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top